Epizyme Inc. (NASDAQ:EPZM) saw an uptick in trading volume on Tuesday . 370,978 shares changed hands during mid-day trading, an increase of 4% from the previous session’s volume of 356,743 shares.The stock last traded at $8.61 and had previously closed at $8.72.

Several brokerages have weighed in on EPZM. Leerink Swann reiterated an “outperform” rating and issued a $39.00 target price on shares of Epizyme in a research note on Tuesday, June 21st. HC Wainwright reiterated a “buy” rating on shares of Epizyme in a research note on Monday, June 20th. Cowen and Company reiterated a “buy” rating on shares of Epizyme in a research note on Monday, June 20th. Mizuho reiterated a “buy” rating and issued a $18.00 target price on shares of Epizyme in a research note on Monday, June 20th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a $26.00 target price on shares of Epizyme in a research note on Monday, June 20th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $23.11.

The firm’s 50 day moving average price is $9.78 and its 200-day moving average price is $10.43. The firm’s market cap is $505.38 million.

Epizyme (NASDAQ:EPZM) last issued its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.49) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.03. Analysts anticipate that Epizyme Inc. will post ($2.19) EPS for the current year.

In other Epizyme news, insider Robert A. Copeland sold 4,000 shares of the company’s stock in a transaction that occurred on Monday, August 1st. The stock was sold at an average price of $10.37, for a total transaction of $41,480.00. Following the sale, the insider now owns 35,538 shares in the company, valued at $368,529.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

A hedge fund recently raised its stake in Epizyme stock. Jennison Associates LLC boosted its stake in shares of Epizyme Inc. (NASDAQ:EPZM) by 252.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 893,913 shares of the biopharmaceutical company’s stock after buying an additional 640,245 shares during the period. Jennison Associates LLC owned approximately 2.14% of Epizyme worth $14,320,000 as of its most recent SEC filing.

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.